Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — EAU Annual Meeting (EAU26) 2026
8 slides from Cg Oncology's conference presentation, Mar 16, 2026
Slide 1: CORE-008 Cohort B: Evaluating Intravesical Cretostimogene in High-Risk, BCG-Exposed NMIBC
A0652 CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed Non-Muscle Invasive Bladder Cancer Trinity J. Bivalacqua, MD, PhD;1* Siamak Daneshmand, MD;2 Eugene Cone, MD;3 Christopher M. Pieczonka, MD;4 Laurence H. Belkoff, DO;5 Matthew Moss
Slide 2: CORE-008 Cohort B: Evaluating Intravesical Cretostimogene Grenadenorepvec
For individual reference only. The information accessed through this QR code is intended solely for individual CORE-008 Cohort B: Evaluating Intravesical reference and should not be altered, modified, or reproduced in any way. Cretostimogene Grenadenorepvec in Patients with High-Risk, BCG-Exposed No
Slide 3: Disclosures
Disclosures ‣ Grants: NIH SBIR, DOD, RO1, AUA Care Foundation (mentor). ‣ Clinical trials: CG Oncology, Ferring Pharmaceuticals. ‣ Scientific Advisory Board: Urogen, CG Oncology, Pfizer. ‣ Co-Founder: OncoSTING LLC (www.OncoSTING.com). 2
Slide 4: Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec's Dual Mechanism of Action
Oncolytic Immunotherapy: Cretostimogene Grenadenorepvec’s Dual Mechanism of Action 3
Slide 5: CORE-008: Phase 2, Multi-Cohort Trial in HR NMIBC
CORE-008: Phase 2, Multi-Cohort Trial in HR NMIBC BCG-Exposed NMIBC BCG-resistant- Persistent or recurrent HG Ta or CIS at the first evaluation following 5 of 6 induction BCG Delayed relapse after adequate BCG- HG recurrence outside of BCG-UR but within 24 mo after last dose of adequate BCG (5+2 dos
Slide 6: Treatment and Assessment Schedule
Treatment and Assessment Schedule Cohort B (BCG- Exposed) ‣ Re-induction allowed for patients with HG Ta and/or CIS at Month 3 ‣ Cystoscopy & Cytology every 3 months with mandatory mapping biopsies at 12 Mo ‣ CT/MRU every 6 months ‣ Treatment is optional in Year 3 5
Slide 7: CORE-008 Cohort B Trial in Progress
CORE-008 Cohort B Trial in Progress ‣ Patients with HR NMIBC whose disease trajectory falls outside the strict FDA guidance of BCG-UR represent a significant unmet need, often lacking access to clinical trials or evidence-based treatment options. ‣ CORE-008 Cohort B evaluates intravesical cretostimo
Slide 8: Thank You
Thank You All Bladder Cancer Patients and Their Families Key Investigators, Study Coordinators, Nurses For individual reference only. Key Collaborators CG Oncology The information accessed through this QR code is intended solely for individual Siamak Daneshmand, USC, Los Angeles, CA Rebecca Tregunna